What a Breakthrough in Ewing Sarcoma Means for Synovial Sarcoma

A new Phase 1/2 trial in Ewing sarcoma, just profiled in Clinical Trial Vanguard and published in Nature Medicine, delivered the kind of result the synovial sarcoma community should be watching closely. The trial paired trabectedin with low-dose irinotecan to target the EWS::FLI1 fusion, the oncogenic driver of Ewing sarcoma. For more than a decade, fusion proteins like EWS::FLI1 and our own SS18::SSX have been called “undruggable.” This trial is one of the clearest signals yet that the next generation of precision oncology can change that.

Why this matters for synovial sarcoma

• Ewing sarcoma and synovial sarcoma are close cousins at the molecular level.
  Both are rare, aggressive cancers defined by a single fusion oncoprotein: EWS::FLI1
  in Ewing, SS18::SSX in synovial sarcoma. Both fusions are intrinsically disordered
  transcription factors, and both have resisted direct drug targeting for decades. A
  win in one fusion-driven sarcoma meaningfully raises confidence in the strategy
  across the family.
• The “indirect attack” strategy is the same one SS research is pursuing. Rather than hitting the fusion protein head-on, the Ewing trial attacks its downstream transcriptional machinery. That is the exact playbook behind the most promising synovial sarcoma programs today: BRD9 protein degraders (CFT8634, FHD-609), WDR5 PROTACs, HDAC inhibitor combinations, and EZH2 inhibitors like tazemetostat. All of them target what the fusion does, not what it is.
• Trabectedin is already a sarcoma drug. This is not a distant translational leap. Trabectedin is approved for soft tissue sarcoma and has been studied in synovial sarcoma patients for years. A positive Phase 1/2 signal in another fusion-driven sarcoma, using a drug already familiar to sarcoma oncologists, is directly relevant to how we think about combination strategies in SS.
• Trial design matters as much as the drug. Ultra-rare fusion-driven cancers cannot rely on traditional large Phase 3 trials. The Ewing study leaned on adaptive design and mechanism-driven endpoints, exactly the framework synovial sarcoma needs as more than 15 companies advance more than 20 investigational therapies into our pipeline. Every successful rare-disease trial design makes the next one easier to run.
• The broader takeaway: fusion oncology is delivering. Larotrectinib proved it in TRK-fusion cancers. Trastuzumab deruxtecan proved it in HER2-low breast cancer. Now trabectedin plus irinotecan is proving it in Ewing sarcoma. Synovial sarcoma is next in line, and the scientific, regulatory, and investor environment has never been more aligned behind our disease.

What we are watching at the Foundation

BRD9 degraders in Phase 1/2 for advanced synovial sarcoma, ongoing HDAC and EZH2 combination strategies, the ECHO mRNA vaccine program targeting SS18-SSX fusion epitopes, and early WDR5 PROTAC work now moving toward translation. Each of these programs borrows from the same fundamental insight the Ewing trial just validated: you can beat a fusion cancer without hitting the fusion directly.

Progress in one fusion-driven sarcoma accelerates progress in all of them. We will keep the community updated as these parallel SS programs read out.

Read the full Clinical Trial Vanguard piece here.

Learn more about the synovial sarcoma clinical trials landscape here.